GlassScriptPhysician profile
Richard Desi
NPI 1942463542
$9,358.89
in general payments reported to CMS, 2019-2025
41 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $566 · 2021: $717 · 2022: $1,430 · 2023: $1,902 · 2024: $1,821 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,212 · Education: $57.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,212.05 |
| Education | $57.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,725.02 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,272.42 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,262.43 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,026.38 | 2019-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $626.98 | 2022-2025 | Dupixent |
| Pfizer INC. | $556.91 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $312.35 | 2021-2023 | |
| Celgene Corporation | $285.19 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $204.39 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $173.33 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $172.79 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $169.38 | 2023-2024 | |
| Genzyme Corporation | $161.77 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $152.52 | 2024-2025 | Iqirvo, Bylvay |
| Ferring Pharmaceuticals INC. | $150.40 | 2019-2023 | Rebyota, Clenpiq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $109.85 | 2023-2025 | Givlaari |
| Shionogi INC | $101.55 | 2019-2020 | |
| Allergan, INC. | $77.46 | 2019-2020 | |
| Lilly USA, LLC | $71.18 | 2024-2025 | Omvoh |
| Eisai INC. | $70.97 | 2019-2025 | |
| Celltrion USA INC. | $65.33 | 2024 | Vegzelma, Zymfentra |
| Romark Laboratories, Lc | $61.52 | 2019-2020 | |
| Incyte Corporation | $53.45 | 2023-2024 | Pemazyre |
| Exelixis INC. | $50.39 | 2019-2022 | |
| Braintree Laboratories, INC. | $48.42 | 2022-2024 | Sutab, Suflave |
| Mallinckrodt Hospital Products INC. | $44.66 | 2023-2025 | Terlivaz |
| Redhill Biopharma INC. | $42.24 | 2022-2023 | Movantik, Aemcolo, Talicia |
| Ironwood Pharmaceuticals, INC | $38.89 | 2022-2023 | Linzess |
| Medtronic, INC. | $37.07 | 2023-2024 | Gi Genius, Minimed 780g |
| Digestive Care, INC. | $30.21 | 2022 | |
| Madrigal Pharmaceuticals | $29.10 | 2024 | Resmetirom |
| Amgen INC. | $24.69 | 2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $22.68 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $21.01 | 2021 | |
| Daiichi Sankyo INC. | $18.75 | 2024 | Injectafer |
| Qol Medical, LLC | $18.18 | 2022 | |
| Intra-Sana Laboratories | $16.56 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ucb, INC. | $14.67 | 2019 | |
| Dynavax Technologies Corporation | $14.06 | 2019 | |
| Endo Pharmaceuticals INC. | $12.09 | 2019 | |
| Ambu INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Desi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.